Ocular Therapeutix Net Worth
Ocular Therapeutix Net Worth Breakdown | OCUL |
Ocular Therapeutix Net Worth Analysis
Ocular Therapeutix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ocular Therapeutix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ocular Therapeutix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ocular Therapeutix's net worth analysis. One common approach is to calculate Ocular Therapeutix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ocular Therapeutix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ocular Therapeutix's net worth. This approach calculates the present value of Ocular Therapeutix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ocular Therapeutix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ocular Therapeutix's net worth. This involves comparing Ocular Therapeutix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ocular Therapeutix's net worth relative to its peers.
Enterprise Value |
|
To determine if Ocular Therapeutix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ocular Therapeutix's net worth research are outlined below:
| Ocular Therapeutix had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 58.44 M. Net Loss for the year was (80.74 M) with loss before overhead, payroll, taxes, and interest of (6.51 M). | |
| Ocular Therapeutix currently holds about 134.54 M in cash with (70.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.75. | |
| Ocular Therapeutix has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Ocular Therapeutix chief scientific officer sells shares worth 26,561 |
Ocular Therapeutix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ocular Therapeutix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ocular Therapeutix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ocular Therapeutix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ocular Therapeutix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocular Therapeutix backward and forwards among themselves. Ocular Therapeutix's institutional investor refers to the entity that pools money to purchase Ocular Therapeutix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 3.7 M | Perceptive Advisors Llc | 2024-09-30 | 3.3 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | Deltec Asset Management Llc | 2024-09-30 | 2.6 M | Octagon Capital Advisors Lp | 2024-09-30 | 2.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.3 M | Braidwell Lp | 2024-09-30 | 2.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 2 M | Summer Road Llc | 2024-06-30 | 14.9 M | Vr Adviser, Llc | 2024-09-30 | 12.8 M |
Follow Ocular Therapeutix's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.58 B.Market Cap |
|
Project Ocular Therapeutix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.89) | (0.84) |
When accessing Ocular Therapeutix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ocular Therapeutix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ocular Therapeutix's profitability and make more informed investment decisions.
Evaluate Ocular Therapeutix's management efficiency
Ocular Therapeutix has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7267) %, meaning that it created substantial loss on money invested by shareholders. Ocular Therapeutix's management efficiency ratios could be used to measure how well Ocular Therapeutix manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.34. The value of Return On Capital Employed is expected to slide to -0.4. At this time, Ocular Therapeutix's Asset Turnover is quite stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.14 | 1.20 | |
| Tangible Book Value Per Share | 1.14 | 1.20 | |
| Enterprise Value Over EBITDA | (3.67) | (3.85) | |
| Price Book Value Ratio | 3.91 | 4.10 | |
| Enterprise Value Multiple | (3.67) | (3.85) | |
| Price Fair Value | 3.91 | 4.10 | |
| Enterprise Value | 243.6 M | 200.8 M |
Ocular Therapeutix benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 20.0109 | Revenue 61.1 M | Quarterly Revenue Growth 0.083 | Revenue Per Share 0.529 | Return On Equity (0.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocular Therapeutix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocular Therapeutix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocular Therapeutix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ocular Therapeutix Corporate Filings
F4 | 27th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 4th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Ocular Therapeutix Earnings per Share Projection vs Actual
Ocular Therapeutix Corporate Management
| William Slattery | Vice Relations | Profile | |
| Todd Anderman | Chief Secretary | Profile | |
| William II | Vice Marketing | Profile | |
| Peter MD | Chief Officer | Profile | |
| Donald Notman | Chief Officer | Profile | |
| Philip Esq | General Counsel | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.